Skip to main content

Table 2 Response rate across the different patient characteristics

From: Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study

  Clinically relevant reduction of migraine days in all migraine types (≥50%)  
Variable Yes (n = 73) No (n = 18) P-value
Gender    0.747
Female 63 (80.8%) 15 (19.2%)  
Male 10 (76.9%) 3 (23.1%)  
Range of age    0.035
0–20 1 (50.0%) 1 (50.0%)  
21–30 8 (57.1%) 6 (42.9%)  
31–40 21 (77.8%) 6 (22.2%)  
41–65 43 (89.9%) 5 (10.4%)  
Ethnicity    0.015
Middle East 30 (66.7%) 15 (33.3%)  
Asian 16 (94.1%) 1 (5.9%)  
Europe 19 (95.0%) 1 (5.0%)  
Rest of the world 8 (88.9%) 1 (11.1%)  
Type of migraine    0.008
Medication overuse headache 7 (50.0%) 7 (50.0%)  
Episodic migraine 29 (87.9%) 4 (12.1%)  
Chronic migraine 37 (84.1%) 7 (15.9%)  
Dose increase    0.369
Yes 10 (71.4%) 4 (28.6%)  
No